Pharmaceutical

Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment

Dewpoint Therapeutics and MTPC have entered a strategic research partnership focusing on the development of TDP-43 small molecule c-mod.

Dec 7, 2024 - 06:00
Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment
Dewpoint Therapeutics and MTPC have entered a strategic research partnership focusing on the development of TDP-43 small molecule c-mod.
Read the original article

Tags:

Previous Article

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Next Article

LEO Pharma’s eczema cream gains MHRA marketing authorisation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen submits sBLA to FDA for NSCLC combination therapy

Aug 28, 2023

Opinion: IVF bans like Alabama’s could cost the lives of children already born

Opinion: IVF bans like Alabama’s could cost the lives o...

Feb 27, 2024

ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope

ASH 2024: Regeneron’s Ordspono faces challenges, but po...

Dec 11, 2024